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Objective: We sought to examine our management and outcome of lung carcinoma
occurring after thoracic organ transplantation.
Methods: We performed a retrospective review of cases of primary lung carcinoma
diagnosed between 1990 and 2000 in patients who have previously undergone
thoracic transplantation at our institution.
Results: Seventeen patients were identified (1 lung and 16 heart transplants). Median
time from transplantation to diagnosis of lung carcinoma was 89 months (range, 46-138
months). Predominant presentation was as an incidental finding at chest radiography
(13/17). All patients had smoked cigarettes before transplantation, with 5 continuing to
smoke after transplantation. Histologic types were squamous (n 11), adenocarcinoma
(n  3), small cell (n  2), and undifferentiated (n  1). Revised International Union
Against Cancer (UICC) clinical stage at the time of diagnosis was stage I or II in 11 of
17 patients. Of these, 9 underwent surgical resection; 2 patients unfit for surgical
intervention had radiotherapy. Surgical procedures were lobectomy (n  5), wedge
excision (n  3), and no resection (n  1). Median survival after diagnosis was 12
months for all patients and 24 months if the tumor was resected. Six patients who had
surgical resection subsequently died (survival of 2, 9, 21, 21, 36, and 67 months); 2
remain alive after 12 and 54 months, respectively.
Conclusions: When possible, surgical intervention should be undertaken for early
stage lung cancer occurring after thoracic transplantation because medium-term
survival is achievable. Sublobar excisions and definitive radiotherapy should be
considered if comorbidity prevents optimal surgical treatment.
Patients who have undergone solid organ transplants are known to havean increased risk of neoplasia compared with that of the generalpopulation. Prognosis of most solid organ tumors occurring in thiscontext is poor, and neoplasia remains the most frequent non–graft-related cause of late deaths after heart transplantation.1 Primary bron-chogenic carcinoma has a particularly poor prognosis in the nontrans-
plant setting and is the leading cause of cancer death in men and the third leading
cause in women in England and Wales.2 The main predisposing factor, cigarette
smoking, is also a predisposing factor for end-stage cardiopulmonary disease. Many
recipients of thoracic transplants are therefore at high risk of bronchogenic carci-
noma. In this article we present a series of 17 thoracic transplant recipients who have
been given a diagnosis of lung cancer at our institution over a 10-year period.
Materials and Methods
Between 1981 and 1999, we performed 2335 thoracic transplantations at our institution. All
patients are followed up on an annual basis or more frequently if clinically indicated.
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Follow-up evaluation includes (inter alia) a chest examination and
chest radiography. Any patients with unexplained respiratory
symptoms or unexplained shadows on chest radiography are in-
vestigated by means of bronchoscopy and computed tomographic
(CT) scanning to exclude lung carcinoma.
Where lung carcinoma was diagnosed, decisions on further
treatment were undertaken jointly by a multidisciplinary team
consisting of thoracic surgeons, chest physicians, medical oncolo-
gists, radiotherapists, radiologists, and transplant physicians. De-
cisions on patient management were individualized and depended
on clinical staging and the patient’s overall clinical condition.
Surgical operations were undertaken by one of 3 surgeons, with the
choice of procedure being left to the individual surgeon’s discre-
tion. After surgical intervention, a preoperative immunosuppres-
sive regimen was continued, with drugs administered orally by
means of a nasogastric tube if the patient was unable to take oral
medication or by means of the intravenous route if gut absorption
was poor. Cyclosporine (INN: ciclosporin) levels were monitored
daily. No additional steroids were given in the postoperative pe-
riod. After diagnosis of lung carcinoma, patients were followed up
on a 3-month basis to assess for clinical or radiologic signs of local
recurrence or distant metastasis. No patients were lost to follow-up
after diagnosis of lung carcinoma.
Data Collection
All transplant recipients who were given a diagnosis of primary
lung carcinoma between 1991 and 2000 were identified by means
of review of patient and pathologic databases. Patients with sec-
ondary lung tumors, lymphomas, and sarcomas were not included
in this series. Additionally, patients in whom bronchoalveolar cell
carcinoma was the indication for transplantation were excluded.
Data were obtained on the basis of a retrospective review of
pathologic records and medical case notes.
Statistical Analysis
Survival analysis was performed by using the life-table method.
Survival was defined as freedom from death from any cause.
Results
Patients
Seventeen patients were identified: 16 had undergone heart
transplantation, and 1 had undergone lung transplantation
(single-lung transplantation with carcinoma in the contralat-
eral lung). The demographic characteristics of these patients
are shown in Table 1. The median age at the time of
diagnosis of lung carcinoma was 60 years (range, 44-71
years). All but one patient was aged 50 years or older at the
time of diagnosis. Lung carcinoma was diagnosed at a
median of 89 months (7.4 years) after transplantation, with
a range of 46 to 138 months. All patients had received
triple-therapy immunosuppression with cyclosporine, pred-
nisolone, and azathioprine, with early withdrawal of pred-
nisolone. Seven patients had received induction therapy
with antithymocyte globulin.
Most patients (13/17) were asymptomatic at presentation
and presented with an incidental abnormality noted on chest
radiography. In only one patient did retrospective review of
previous radiographs show a missed lesion. Presenting
symptoms in the other 4 patients were shortness of breath
(n  1), cough (n  1), pain (n  1), and neck mass (n 
1). Definitive (histologic) diagnosis was made at bronchos-
copy (6/17), CT biopsy (4/17), mediastinoscopy (1/17),
thoracotomy or thoracoscopy (5/17), and cervical lymph
node biopsy (1/17).
TABLE 1. Clinical characteristics
Case
no. Sex
Age at
transplantation (y) Diagnosis
Smoking history
at transplantation
Known smoker
after transplantation
Interval from transplantation to
diagnosis (mo)
1* M 50 Ischemic Exsmoker No 100
2 M 67 Ischemic Exsmoker Yes 46
3 M 48 Ischemic Still smoking No 107
4 M 61 DCM Still smoking Yes 107
5 M 63 Ischemic Still smoking Yes 86
6 M 50 Ischemic Exsmoker No 89
7 M 49 Ischemic Exsmoker No 101
8 M 46 Ischemic Still smoking No 48
9 M 49 Ischemic Exsmoker No 133
10 M 54 DCM Exsmoker No 53
11 M 67 Ischemic Exsmoker No 83
12 M 52 Ischemic Exsmoker No 132
13† M 39 A1A Exsmoker No 59
14 M 59 Ischemic Exsmoker No 136
15 F 55 Ischemic Exsmoker No 138
16 M 52 DCM Still smoking Yes 84
17 M 58 Ischemic Exsmoker No 89
Ischemic, Ischemic cardiomyopathy; DCM, dilated cardiomyopathy; A1A, Alpha-1 antitrypsin deficiency.
*Heterotopic heart transplant.
†Single-lung transplant with carcinoma in contralateral lung.
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Staging and Pathology
All patients underwent pretreatment staging by means of a
CT scan. In addition, some patients underwent bronchos-
copy (16/17), mediastinoscopy (6/17), positron emission
tomography (2/17), and thoracoscopy (2/17). Table 2 shows
the clinical stage at the time of diagnosis. Staging was based
on the revised international American Joint Commission for
Cancer/International Union Against Cancer (AJCC/UICC)
system.3 Eleven patients had stage I or stage II disease at the
time of diagnosis. There was no correlation between the
presence of symptoms and clinical stage, with the majority
presenting as incidental radiographic findings, regardless of
clinical stage. Histologic classification is shown in Table 2.
Management
The 6 patients who had advanced disease (stage III or IV)
were treated with chemotherapy, palliative radiotherapy, or
a combination of both. The remaining patients were consid-
ered for surgical resection. Two patients with surgically
resectable disease were unsuitable candidates, one because
of poor respiratory reserve and another because of heart
failure as a result of transplant coronary artery disease.
These 2 patients received radiotherapy (one palliative and
one definitive). The remaining 9 patients with clinical stage
I or II disease proceeded to thoracotomy. Details of surgical
procedures performed are shown in Table 3. In one patient
a central right upper lobe tumor was found to breach the
oblique fissure, requiring a right pneumonectomy for surgi-
cal clearance; because the patient was not fit for pneumo-
nectomy and the tumor was not amenable to wedge exci-
sion, no resection was performed. Surgical resection was
undertaken in 8 patients (Table 3). Three patients had sub-
lobar resections. The 3 sublobar excisions were a lingula-
sparing left upper lobectomy, a wedge excision of a tumor
breaching the horizontal fissure (a wedge excision was done
in preference to bilobectomy), and a wedge excision of an
apical left lower lobe tumor. All sublobar excisions were
done because of concerns about respiratory reserve. Patho-
logic staging led to upstaging in one patient (case 16), in
whom N2 paratracheal nodes excised at the time of the
operation were positive for carcinoma.
Outcomes
Figure 1 shows actuarial survival after diagnosis of lung
carcinoma. Median survival was 12 months, and 5-year
survival was 19%. No patient with stage II, III, or IV disease
survived up to a year after diagnosis. The 5-year survival for
patients with clinical stage I disease at diagnosis was 35%.
Discussion
Demographic characteristics of patients who had lung car-
cinoma in our transplant population were similar to those of
the nontransplant lung carcinoma population. As in the
nontransplant population, lung carcinoma in the transplant
recipient was associated with tobacco smoking, and patients
were predominantly in their sixth or seventh decade. Al-
though there is evidence of increased prevalence of most
solid tumors in transplant recipients, the association be-
tween immunosuppression and lung carcinoma is less cer-
TABLE 2. Staging, treatment, and outcome
Patient no. T2 N0 M0 UICC Symptoms Site Cell type Treatment Status
Survival
(d)
1 T2 N0 M0 I No RUL Squamous Surgery Dead 663
2 T2 N2 M1 IV Yes RUL Squamous RT Dead 39
3 T1 N0 M0 I No LLL Squamous Surgery Dead 1007
4 T1 N0 M0 I No LUL Squamous RT* Dead 122
5 T2 N0 M0 I No RUL Adeno Surgery Dead 2040
6 T2 N0 M0 I No LUL Adeno Surgery Dead 658
7 T2 N1 M0 II No RML Squamous Surgery Dead 344
8 T2 N0 M0 I No RUL Squamous Surgery Alive 1608‡
9 T4 N3 M0 III Yes LUL Small Cell Chemo, RT Dead 30
10 T4 N2 M1 IV No RUL Undifferentiated Chemo Dead 269
11 T3 N1 M1 IV Yes RML Small Cell Chemo Dead 188
12 T2 N1 M0 II No RUL Squamous Chemo, RT† Dead 300
13 T2 N2 M0 III No RLL Squamous RT Dead 199
14 T2 N0 M0 I Yes LLL Adeno Surgery Dead 65
15 T2 N0 M0 I No RUL Squamous RT* Alive 461‡
16 T1 N0 M0 I No RUL Squamous Surgery Alive 375‡
17 T2 N2 M0 III No RUL Squamous RT Dead 336
RUL/RML/RLL, Right upper/middle/lower lobe; RT, radiotherapy; LUL/LLL, left upper/lower lobe; Adeno, adenocarcinoma; Chemo, chemotherapy.
*Unfit for lung resection surgery.
†Thoracotomy or lobectomy not feasible (unfit for pneumonectomy).
‡Censored follow-up.
General Thoracic Surgery Anyanwu et al
1192 The Journal of Thoracic and Cardiovascular Surgery ● December 2002
G
TS
tain.4 Although most studies of heart transplant recipients
have reported a higher incidence of lung carcinoma in
thoracic transplant recipients compared with that in the
general population, this is not necessarily because of im-
munosuppression because heart transplant recipients are a
selected group at higher risk of development of lung carci-
noma by virtue of previous smoking and more advanced age
(half of our heart transplant recipients are older than 50
years).
Several indirect observations from our cohort tend to
support the view that immunosuppression is not a primary
causative factor in lung carcinoma. We did not experience
any lung carcinoma in our young recipients (the youngest
patient to have lung carcinoma was 44 years old at the time
of diagnosis), despite many of them having received immu-
nosuppression for up to 10 years. Second, we have not
observed lung carcinoma in any life-long nonsmoking re-
cipients. Third, we did not observe lung carcinoma in any
transplanted lungs. Although we do transplant lungs from
donors with a smoking history, most of these tend to be
young and carefully selected to exclude smoking-related
lung disease. Finally, there was an association between lung
Figure 1. Survival after diagnosis of lung carcinoma (n  17).
TABLE 3. Operations for lung carcinoma in transplant recipients
Sex/age (y)
Stage
pTNM Cell type Site Status
Survival
(mo) Cancer recurrence?
Lobectomies
M/58 T2 N0 Squamous RUL Dead
(carcinoma)
21 Bony metastases 14 mo
M/70 T2 N0 Adeno RUL Dead
(cardiac)
67 No
M/58 T2 N0 Squamous RML Dead
(carcinoma)
9 Local recurrence 9 mo Completion
right pneumonectomy; died of
postoperative infection in left lung
M/71 T2 N0 Squamous LLL Dead
(postoperative
respiratory
failure)
2 Not applicable
M/59 T1 N2 Squamous RUL Alive 12 No
Wedge or segment excisions
M/57 T2 N0 Adeno LUL apex Dead
(carcinoma)
21 Yes
M/56 T2 N0 Squamous LLL apex Dead (graft
vasculopathy)
36 No
M/50 T1 N0 Squamous RML/RUL Alive 54 No
RUL/RML/RLL, Right upper/middle/lower lobe; Adeno, adenocarcinoma; LUL/LLL, left upper/lower lobe.
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carcinoma and ischemic heart disease: although ischemic
heart disease was the indication for heart transplantation in
40% of patients treated at our center, it was the primary
underlying disease in 80% of those with lung carcinoma.
Similar observations were made by Goldstein and col-
leagues,5 who reported a series of 9 patients with lung
carcinoma after heart transplantation, of whom 8 had isch-
emic heart disease (the ninth patient had idiopathic cardio-
myopathy but was a smoker, as was the case in the non-
ischemic patients in our cohort). Whether
immunosuppression does increase the risk in patients al-
ready predisposed to lung carcinoma is uncertain, but it does
not appear to precipitate lung neoplasia in those recipients
who are otherwise not at risk.
The predominant presentation was as an incidental find-
ing on chest radiography. It is of note that 6 of 17 patients
had advanced disease despite regular follow-up, pointing to
the inadequacy of chest radiography as a screening tool for
lung carcinoma.6,7 Results from other series have shown an
even greater prevalence of advanced disease (Table
4).4,5,8-10 Preliminary results of screening with low-dose
spiral CT scanning11 are more promising, and this modality
of screening might be considered as an alternative to chest
radiography. There might be also a case for performing a
lung CT scan as part of assessment for heart transplantation
in patients with a history of smoking in a bid to detect occult
carcinomas that might later become apparent.5 However, in
our series the time interval between transplantation and
cancer diagnosis in our patients was sufficiently long to
suggest that clinically detectable cancers were not missed at
assessment. In our series 11 patients had potentially curable
disease. However, 2 patients did not undergo surgical inter-
vention because of comorbidity. In one patient with border-
line lung function, thoracotomy was undertaken, but no
resection was performed because the tumor required a right
pneumonectomy for surgical clearance.
Surgical intervention, however, remains the treatment of
choice, and where undertaken, medium-term survival was
achievable. We undertook successful surgical resection in 8
patients, and this is reflected in a relatively promising me-
dian survival (for the entire cohort) of 12 months compared
with those of other series, which have reported a median
survival of 27 days8 and 3 months.5 However, optimal
surgical treatment might not be possible because of im-
paired respiratory function. Our observation has been that
thoracic transplant recipients do not tolerate extensive lung
resection in the same manner as nontransplant recipients.
Many patients, by virtue of previous smoking (which has
caused end-stage failure of one organ), invariably have a
degree of chronic lung damage, even in the presence of
normal spirometry.
Additionally, transplant recipients are more prone to
major lung infection. Two of our patients died because of
postoperative infection in the residual lung. The less the
residual lung volume after resection, the more the likelihood
that major infection will lead to acute decompensation. We
performed one pneumonectomy, a completion pneumonec-
tomy for local recurrence 9 months after complete resection
of a T2 tumor by means of lobectomy. This patient died of
postoperative respiratory failure precipitated by infection in
the remaining lung. Concerns about residual cardiopulmo-
nary function led us to perform 3 sublobar excisions. In 2 of
these patients, the ideal anatomic operation for surgical
clearance was pneumonectomy. Of the 8 patients who un-
derwent surgical intervention, 1 died in the postoperative
period, and 3 subsequently died of local recurrence (one of
whom had a wedge excision). The other 4 patients did not
show any local recurrence (Table 3), with 3 surviving up to
3 years (of whom 2 had sublobar excisions). When a pneu-
monectomy or lobectomy cannot be undertaken (as might
often be the case in the transplant recipient), a sublobar
excision remains a useful option. Definitive radiotherapy
TABLE 4. Comparisons with other series
Reference n
Smoking
history
Median time from
transplantation to
diagnosis (mo)
Histology:
non–small
cell
Early cancer
(stage I/ II)
Surgical
resection
Median
survival
(mo)
Present study 17 All 84 15/17 11/17 8 12
Pham and colleagues,
1995, Pittsburgh8
10 ? 19 10/10 2/10 3 1
Goldstein and colleagues,
1996, New York5
9 All 38 5/9 1/8 0 3
Taniguchi and
colleagues, 1997,
Oklahoma4
4 All 70 3/4 1/4 3 8
Delcambre and
colleagues, 1996,
France9
4 All 63 3/4 1/4 1 3
Flemming and colleagues,
1994, Missouri10
3 All 12 3/3 2/3 2 18
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should be considered in those patients who cannot tolerate
any level of surgical resection. One of our patients (who was
unsuitable for lung resection) remains alive and free of
cancer 15 months after diagnosis after receiving definitive
radiotherapy with the continuous, hyperfractionated, accel-
erated radiotherapy regimen.12 Patients with stage I or II
disease should therefore not be turned down for curative
therapy on the grounds of previous transplantation alone.
Surgical intervention did not present any specific technical
difficulties related to previous transplantation, except in a
right upper lobectomy in a patient whose right lung was
densely adherent to a heterotopically placed heart graft.
Complete tumor clearance was achieved without compro-
mising the heterotopic heart, and this patient survived 21
months.
Because this is an uncommon clinical problem, our study
is necessarily limited by small numbers. Also, our treat-
ments have not been randomly or systematically assigned,
being largely dependent on physician preference. However,
our findings are in line with those of other published series
(Table 4). Our data should help guide other clinicians faced
with this uncommon clinical scenario. A high index of
suspicion is required in the follow-up of transplant recipi-
ents with a history of smoking with a view to detecting
cancers at an early stage because this seems to present the
only hope for averting what is otherwise a likely dismal
outcome. Alternative screening modalities, such as CT
scanning and positron emission tomography, might improve
detection of early tumors, but their role in this setting is yet
undetermined.
References
1. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The
Registry of the International Society for Heart and Lung Transplan-
tation: seventeenth official report-2000. J Heart Lung Transplant.
2000;19:909-31.
2. Coleman MP, Babb P, Mayer D, Quinn MJ, Sloggett A. Cancer
survival trends in England and Wales, 1971-1995: deprivation and
NHS Region. London: Office for National Statistics; 2001.
3. Mountain CF. Revisions in the International System for Staging Lung
Cancer. Chest. 1997;111:1710-7.
4. Taniguchi S, Cooper DK, Chaffin JS, Zuhdi N. Primary bronchogenic
carcinoma in recipients of heart transplants. Transpl Int. 1997;10:
312-6.
5. Goldstein DJ, Austin JH, Zuech N, Williams DL, Stoopler MB,
Michler RE, et al. Carcinoma of the lung after heart transplantation.
Transplantation. 1996;62:772-5.
6. Strauss GM. Randomized population trials and screening for lung
cancer: breaking the cure barrier. Cancer. 2000;89:2399-421.
7. Gavelli G, Giampalma E. Sensitivity and specificity of chest X-ray
screening for lung cancer: review article. Cancer. 2000;89(suppl 11):
2453-6.
8. Pham SM, Kormos RL, Landreneau RJ, Kawai A, Gonzalez-Cancel I,
Hardesty RL, et al. Solid tumors after heart transplantation: lethality of
lung cancer. Ann Thorac Surg. 1995;60:1623-6.
9. Delcambre F, Pruvot FR, Ramon P, Noel C, Pol A, Jaillard-Thery S,
et al. Primary bronchogenic carcinoma in transplant recipients. Trans-
plant Proc. 1996;28:2884-5.
10. Fleming RH, Jennison SH, Naunheim KS. Primary bronchogenic
carcinoma in the heart transplant recipient. Ann Thorac Surg. 1994;
57:1300-1.
11. Kaneko M, Kusumoto M, Kobayashi T, Moriyama N, Naruke T,
Ohmatsu H, et al. Computed tomography screening for lung carci-
noma in Japan. Cancer. 2000;89(suppl 11):2485-8.
12. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M.
Continuous, hyperfractionated, accelerated radiotherapy (CHART)
versus conventional radiotherapy in non-small cell lung cancer: ma-
ture data from the randomised multicentre trial. CHART Steering
committee. Radiother Oncol. 1999;52:137-48.
Discussion
Dr Thomas J. Kirby (Cleveland, Ohio). This obviously rep-
resents a very unusual group of patients with primary lung carci-
noma many years after heart-lung transplantation.
My comments have to do with the title of your article, along
with your conclusions. You focus a great deal on the word “epi-
demiology.” It is very difficult to extrapolate any epidemiologic
parameters from a group of 17 patients for whom the average time
after transplantation or time to diagnosis was 8.5 years after
transplantation. In 8.5 years after a heart or a lung transplantation,
the transplantation cohort is at least cut in half or two thirds by
patient deaths related to side effects of immunosuppression or
chronic rejection. Therefore, you would not be able to comment on
2 primary facets in epidemiology of any disease: incidence and
prevalence. If your premise is that somehow the incidence and
prevalence of lung cancer is different in your study group, then you
should compare your group with the control arm: the incidence and
prevalence of lung cancer in the normal smoking population.
You mentioned that the immunosuppression received by these
patients represented a risk factor, but this cannot be the case,
otherwise we would see an increased incidence in lung cancer after
liver and kidney transplantations, for example. Therefore, standard
immunosuppression is not a causative factor in development of
lung carcinoma in your group.
The second point has to do with the management of these
patients. I could not tell how you decided to do a wedge resection
versus a lobectomy versus a pneumonectomy, and I would like you
to comment on your choice of operations.
Not so much in your talk but in your article, you mentioned
turning down one patient in whom you said the cancer had crossed
the major fissure from the right upper lobe into the middle lobe.
Most thoracic surgeons would perform a segmental resection or a
wedge resection of the right middle lobe, lower lobe, or both
combined with a right upper lobectomy and not deem the patient’s
condition inoperable.
Having to do with intraoperative staging, you started out pre-
operatively with 9 patients who you took to the operating room
with clinical stage I or II disease. Postoperatively, I did not see you
change the stage of any of those patients. Can you comment on
how you staged the disease of these patients intraoperatively. If
you found N2 or N3 disease intraoperatively, would you still
perform resection? Also, what role do you believe mediastinos-
copy has in this patient group? Do you really believe that pneu-
monectomy is an acceptable operation in this group of patients?
Last, you did not mention kidney function in these individuals.
Every one of them has impaired kidney function, which obviously
predisposes to complications postoperatively. At least 50% of
Anyanwu et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 6 1195
G
TS
patients will have significant renal dysfunction and azotemia 8 to
10 years after a heart or lung transplant. This is an important factor
to consider preoperatively and to closely monitor postoperatively.
Dr Anyanwu. Thank you very much for your questions, Dr
Kirby. As regards extrapolating epidemiology, I deliberately did
not comment on the incidence or prevalence of lung cancer in this
group for the reasons that you described. There are difficulties in
analyzing cancers that occur in patients who have had a transplant.
Most workers have used actuarial methods to describe freedom
from cancer, but as we heard in the article presented 2 days ago by
Dr Grunkemeier, there are problems with using actuarial methods
to describe nonfatal events. Therefore, it is very difficult in any
way to attempt to define the prevalence or incidence of cancer in
any transplanted cohort, which is why we have not attempted to do
that, and more so, from 17 of over 2000 patients who have
undergone transplantation in our institution, half of whom do not
survive 10 years, it is very difficult to make any definitive com-
ment on the incidence or prevalence.
As regards the choice of operation, this is generally left up to
the surgeon and is determined by the tumor location, as well as the
lung reserve. Many of these patients have comorbidity. Several of
them, as I said, have gone up to 7 or 8 years after transplantation,
and by definition, most of them would have some degree of
transplant coronary artery disease. These patients, in our experi-
ence, do not tolerate lung resection in the same way as the standard
nontransplant patient. We lost 2 patients who had infection in the
residual lung to a degree of infection that we would have expected
to resolve were they not transplant patients. Therefore, in these
patients the more lung you take out, the less there is to cope with
infective complications. The 2 patients who had wedge excisions
would have required a bilobectomy or pneumonectomy for ideal
surgical clearance, which we believed they would not survive on
the basis of their lung function and comorbidity. This has not been
a bad strategy because 1 of them is still alive after 4 years, and the
other died after 3 years with no cancer recurrence.
As regards the role of pneumonectomy, our present practice is
that we would be very pushed to perform a pneumonectomy in this
patient group. As I said, we performed one completion pneumo-
nectomy, and the left lung could not cope with infection, to which
these patients are predisposed. Therefore, we would be very re-
luctant now to perform a pneumonectomy, which is the reason why
we performed an open-and-close thoracotomy in 1 patient who had
potentially resectable disease by means of pneumonectomy. That
tumor was a central tumor that breached the fissure, and for
adequate anatomic clearance, it would have required a pneumo-
nectomy—and that was a right-sided pneumonectomy in a patient
in his seventh decade—and there was not adequate pulmonary
reserve. The patient was referred to the radiotherapist, who did not
believe there was adequate reserve for radical radiotherapy either,
and therefore that patient had palliative treatment.
As regards the staging, the staging I have presented was the
preoperative staging. One of the patients was found to have N2
disease on pathologic examination, and that was one of the patients
who had a lobectomy, and he remains alive after a year.
As for the role of mediastinoscopy, we apply the same practice
that we apply to the rest of our patients with cancer, and we
perform mediastinoscopy only in those patients with suspicious
disease on CT scans, and by suspicious we mean lymph nodes of
about 1 cm or more.
As regards renal function, as you said, most patients have some
degree of impaired renal function, and in the patient who had
radical radiotherapy for stage II tumor, that was the major consid-
eration because this patient had transplant coronary artery disease
and impaired renal function, and we believed that subjecting the
patient to a major operation would tip the patient into permanent
renal replacement.
Dr Valerie W. Rusch (New York, NY). I think that although the
numbers of patients in your series are small, one of the striking
findings is the absolutely dismal outcome for patients who had
higher than stage I disease. In a way this is similar to what we have
seen at our institution, Memorial Sloan-Kettering in New York,
and other large cancer centers with respect to patients who have
either underlying chronic lymphocytic leukemia or have previ-
ously been treated for Hodgkin’s disease. In those instances the
outcome for patients who have greater than stage I, or in some
cases stage II, disease is related to their complete inability to
tolerate both chemotherapy and radiation because of poor marrow
reserve. Would you comment a bit further on those patients? It
certainly does raise the issue that you mentioned briefly, which is
the consideration of perhaps more extensive screening in this
high-risk population, which you have already defined so well, with
a low-dose helical CT scan.
Dr Anyanwu. Unfortunately, I cannot comment directly on the
patients who were treated with palliative chemotherapy because
most of them were treated at a nearby oncology unit outside of our
institution rather than at our institution. Therefore, I cannot really
give you details as to what considerations were taken into account
in providing them with the treatment.
As regards the screening of this population, in our cohort,
because most of the tumors occurred a median of 7 years after
transplantation, it is unlikely that any form of preoperative screen-
ing would have been of benefit, but in other series there is a
suggestion that some of the tumors had predated the transplanta-
tion, and I think there might be a role for CT or positron emission
tomography scanning in these patients if there is thought to be a
high suspicion of cancer.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). As we try to
expand the donor pool, more lungs are being used from donors
with a smoking history. Would you be able to tell us how many out
of the 2000 thoracic transplantations that you reported on were
lung transplantations, and do you have any information on the
smoking history of the donors? Finally, what is your institutional
policy on the use of donors with a smoking history?
Dr Anyanwu. Of our transplantations, about 700 were lung
or heart-lung transplants, and a good proportion of those were
in ex-smokers. We do not consider smoking per se as a selective
criteria for accepting donors, and usually, regardless of the
smoking history, if other criteria are met, we use the donor
lungs. Having said that, as I said earlier, none of these lungs
have gone on to have cancer, and some of these lungs have gone
15 to 20 years after transplantation in our heart-lung cohort.
Dr Joseph B. Shrager (Philadelphia, Pa). Congratulations on
what I think is your third original presentation at this conference,
which is probably some sort of a record.
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Although you suggested that epidemiologically there does not
seem to be a role played by the immunosuppression in the cause of
these cancers, there was, in fact, a preponderance of squamous cell
carcinomas among these tumors, and this in an era when most of
our bronchogenic carcinomas are adenocarcinomas. I am not a
virologist, but I know there has been some suggestion that squa-
mous cell carcinomas in some body sites are associated with
certain viral infections. Because the immunosuppression that these
patients receive certainly depresses cell-mediated immunity and
because this might potentiate these viral infections, perhaps there
is a role played by immunosupression in these cases.
Dr Anyanwu. Well, in our series I think it is just a chance
finding, because 2 of the previous studies found a predominance of
small cell cancers, and we found a predominance of non–small cell
cancers. I think the numbers are too small, and what we are
observing, we are just observing by chance. Therefore, I would not
actually say there is a linkage between the cell type and immuno-
suppression at this stage.
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